Search
Close this search box.

Category: Asean

Zoom Leads A Workplace Revolution

Major new brand campaign developed with Colin Jost’s No Notes Productions lampoons bad tech and champions the employees who suffer for it SAN JOSE, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) — Today, on behalf of employees everywhere, Zoom announced the launch of a major brand campaign developed with Colin Jost’s No Notes Productions lampooning the […]

One New Star Shines in the MICHELIN Guide Doha’s Second Edition

Group Photo 1 restaurant is promoted to One MICHELIN Star, while 2 others retain their Stars 4 new Bib Gourmand distinctions added, bringing the total to 8 Bib Gourmand restaurants in Doha A total of 44 restaurants are listed in the MICHELIN Guide Doha 2026 selection DOHA, Qatar, Dec. 10, 2025 (GLOBE NEWSWIRE) — Doha’s […]

Mavenir Confirms Refocus Strategy on Mobile Core and AI Vision With Expanded Leadership Team to Accelerate AI-Native Network Strategy

RICHARDSON, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) — Mavenir, the software company building AI-by-design mobile networks, today announced a strong leadership team to accelerate its vision for telco-first, cloud-native, AI-by-design networks. This transformation follows the company’s recent recapitalization and aligns with a refreshed product strategy focused on mobile core, AI-enabled automation, and cloud-native platforms. New […]

EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025

Recognition follows a vote by professional and active traders, highlighting the critical role of execution quality in institutional-grade trading Best Broker for Execution at the Professional Trader Awards 2025 – EBC Financial Group LONDON, Dec. 08, 2025 (GLOBE NEWSWIRE) — EBC Financial Group (“EBC”) has been named Best Broker for Execution at the Professional Trader Awards 2025, […]

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease features A 12-day manufacturing time resulted in a vein-to-vein time […]

Recent Posts